Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA
NEW YORK, NY / ACCESSWIRE / April 25, 2017 / Markets rallied Monday after Centrist candidate Emmanuel Macron, an advocate of the European Union, won the first round of the French presidential election. Investors also appear to be gearing up for a busy earnings week as over 190 S&P 500 companies are scheduled to report results. The Dow Jones Industrial Average gained 1.05 percent to close at 20,763.89, while the S&P 500 increased 1.08 percent to close at 2,374.15. The Nasdaq touched an all-time high of 5,989.92 before settling to close at 5,983.82, up 1.24 percent on the day.
"Having seen the results of the French election over the weekend, investors are now taking a disaster-avoided view of markets, so all of the risk-off trades are unwinding and risk-on trades put on," said Art Hogan, chief market strategist at Wunderlich Equity Capital Markets in New York.
RDI Initiates Coverage on:
Achillion Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=ACHN
XOMA Corp.
https://ub.rdinvesting.com/news/?ticker=XOMA
Achillion Pharmaceuticals' shares declined 11.81 percent to close at $3.21 a share on Monday. The stock traded between $3.15 and $3.74 on volume of 4.65 million shares traded. On April 22nd, the company reported mixed results from the ongoing phase 2 '604 Study' being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen). Shares of Achillion Pharmaceuticals have fallen approximately 22.28 percent year-to-date.
"The goal of the Janssen HCV development program is to optimize treatment outcomes by providing a novel, simplified therapeutic option with high efficacy, safety, and a shorter treatment duration to address a broad range of patients living with HCV. Importantly, in this study 100% SVR12 was achieved despite the presence of NS5A polymorphisms, which can reduce the efficacy of other HCV regimens, that were observed at baseline," commented David Apelian, M.D., Ph.D., Chief Medical Officer at Achillion.
Access RDI's Achillion Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=ACHN
XOMA's shares fell 8.02 percent to close at $7.11 a share on Monday. The stock traded between $6.87 and $7.59 on volume of 231,208 shares traded. On Monday, the company reported positive Phase 2 proof-of-concept results for X213, a monoclonal antibody, in physiological hyperprolactinemia (HPRL). Shares of XOMA have gained approximately 68.48 percent year-to-date.
"This proof-of-concept study was an important milestone in demonstrating the potential efficacy of this novel antibody. We believe that X213 could be a treatment option for a wide range of patients with hyperprolactinemia including prolactinoma and anti-psychotic induced HPRL as the signs and symptoms are similar irrespective of the etiology," said Jim Neal, Chief Executive Officer of XOMA.
Access RDI's XOMA Research Report at:
https://ub.rdinvesting.com/news/?ticker=XOMA
Our Actionable Research on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and XOMA Corporation (NASDAQ: XOMA) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing;
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
